Arena Pharmaceuticals to present Phase 3 BLOSSOM trial outcomes at Obesity 2009 Arena Pharmaceuticals, Inc. announced today that lorcaserin will be highlighted in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Culture in Washington, DC. The line-up carries a late-breaking abstract oral display of outcomes from BLOSSOM , a Stage 3 trial for which Arena reported positive, highly significant top-line outcomes in September. Arena will also present fresh data analyses from lorcaserin’s successful Phase 3 pivotal system in oral and poster sessions. In an independent medical symposium, expert academic physicians and researchers will spotlight the 5HT-2C system for weight management. The positive results from our Stage 3 pivotal plan highlight lorcaserin’s potential to supply physicians with a treatment option that combines three essential attributes – efficacy, security and tolerability ‘ – critical to broad applicability in nearly all their patients to help manage fat and improve cardiometabolic health,’ stated William R.Therefore, it stands to cause that circumcision should protect against the development of some full cases of prostate cancer. This is what lead writer Jonathan L. Wright, MD, an affiliate marketer investigator in the Hutchinson Center’s Public Wellness Sciences Division, and his colleagues set out to check. Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic tumor patientsNew antenna-like device makes breast cancer surgery less complicated for surgeonsViralytics enters into medical trial collaboration contract with MSDFor their research, the investigators analyzed details from 3,399 men .